Correlation of circulating 17β-oestradiol with haemostatic factors in healthy postmenopausal women

Haemostasis

Volumn 29, Issue 6, 2000, Pages 336-342

  Mukherjee, Manjari ^a,b   DeLorenzo, Ferruccio ^a   Kadziola, Zbigniew ^a   Rutlin, Accabre ^a   Ranlall, Nancy ^a   Sembhi, Kuldip ^a   Dawson, Gloria ^a   Kakkar, Vijay V ^a  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b Cumballa Hill Hospital   (India)

Author keywords

17 Oestradiol; Antithrombin III; Hormone replacement therapy. Endogenous thrombin potential; Prothrombin fragments; 2 Antiplasmin

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN III; ESTRADIOL; PROTHROMBIN; THROMBIN; ANTIPLASMIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7; PEPTIDE FRAGMENT; PROTHROMBIN FRAGMENT 1.2;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; ESTRADIOL BLOOD LEVEL; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBIN TIME; BLOOD; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST;

ADULT; AGE FACTORS; ANTIPLASMIN; ANTITHROMBIN III; BLOOD COAGULATION FACTORS; BODY MASS INDEX; ESTRADIOL; FACTOR VII; FEMALE; HEMOSTASIS; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PEPTIDE FRAGMENTS; POSTMENOPAUSE; PROTHROMBIN; STATISTICS, NONPARAMETRIC;

EID: 0033223817     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Stevenson JC, Crook D, Godsland IF, Collins P, Whitehead MI: Hormone replacement therapy and the cardiovascular system: Nonlipid effects. Drugs 1994:47(suppl 2):35-41.
2. Berga SL: Hormonal management of sick menopausal women. Obstet Gynecol Clin North Am 1994;21: 231-244.
3. Marten SK: Complications of menopause and risks and benefits of estrogen replacement therapy. J Am Acad Nurse Pract 1993;5:55-61.
4. Griffing GT, Allan SH: Estrogen replacement therapy at menopause: How benefits outweigh risks. Postgrad Med 1994;96:131-140.
5. Kay-Tee K: Hormone replacement therapy again: Risk-benefit relation differs between populations and individuals. Br Med J 1998;316: 1842-1844.
6. Grodstein F, Stampfer MJ, Colditz GA, Willet WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hanikinson Se, Hunter DJ, Hennekens CH, Speizer FE: Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-1775.
7. Daly E, Versey MP, Hawkins MM, Carson JL, Gough P, Marsh S: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-980.
8. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996;348:981-983.
9. Winkler UH, Kramer R, Kwee B, Schindler AE: Östrogensubstitution in der Postmenopause, Blutgerinnung und Fibrinolyse: Vergleich einer neuartigen transdermalen Östradiol-Behandlung mit der oralen Therapie mit konjugierten Östrogenen. Zentralbl Gynäkol 1995;117: 540-548.
10. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucina F, Guetta V, Waclawiw M, Cannon RO: Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-690.
11. Walsh WB, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279: 1445-1451.
12. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD: Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68: 392-395.
13. Salch AA, Dorey LG, Dombrowski MP, Ginsburg KA, Hirokawa S, Kowalczyk C, Hirata J, Bottoms S, Cotton DB, Mammen EF: Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 1993;169:1554-1557.
14. Conrad J, Gompel A, Pelissiar C, Mirabel C, Basdevant A: Fibrinogen and plasminogen modifications during oral ocstradiol therapy. Fertil Steril 1997;68:449-453.
15. Fröhlich M, Schunkert H, Hense HW, Tropitzsch A, Hendricks P, Döring A, Reigger GA, Koenig W: Effects of hormone replacement therapies on fibrinogen and plasma viscosities in postmenopausal women. Br J Haematol 1998;100:577-581.
16. Kroon U-B, Silverstolpe G, Tengborn L: The effects of transdermal estradiol and oral conjugated estrogens on hemostasis variables. Thromb Haemost 1994;71:420-423.
17. The Writing Group for Estradiol Clotting Factors Study: Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year double-blind, placebo-controlled study. Thromb Haemost 1996;75:476-480.
18. Mukherjee M, Sembhi K, Kakkar VV: Interference of an activity of tissue-type plasminogen activator in human plasma by endogenous factors. Blood Coagul Fibrinolysis 1996;7:491-496.
19. Mukherjee M, Scully MF, Thomas M, Jewitt D, Kakkar VV: The potential thrombogenic action of a non-ionic radiographic contrast medium used during coronary angiography is offset by heparin during coronary angioplasty. Thromb Haemost 1996;76:679-681.
20. Weilders S, Mukherjee M, Michiels J, Rijkers DTS, Cambus J-S, Knebel RWC, Kakkar VV, Hemker HC, Béguin S: The routine determination of the endogenous thrombin potential: First results in different forms of hyper- and hypocoagulability. Thromb Haemost 1997;77:629-636.
21. Paganini-Hill A: Estrogen replacement therapy and stroke. Prog Cardiovasc Dis 1995;38:223-242.
22. Lip GYH, Blann AD, Jones AF, Beevers DG: Effects of hormone replacement therapy on haemostatic factors, lipid factors and endothelial function in women undergoing surgical menopause: Implications for prevention of atherosclerosis. Am Heart J 1997;134:764-771.
23. DeLorenzo F, Mukherjee M, Kadziola Z, Suleiman S, Kakkar VV: Association of overall adiposity rather than body mass index with lipids and procoagulant factors. Thromb Haemost 1998;80:603-606.
24. Scarabin P-Y, Alhenc-Gclas M, Plu-Bureau G, Taisne P, Agher R, Aiach M: Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: A randomized controlled trial. Arterioscler Thromb Vase Biol 1997;17:3071-3078.
25. Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, Sacchi A, Pontecorvi A: Molecular basis of estrogen regulation of Hageman factor XII gene expression. Endocrinology 1995;136:5076-5083.